Movatterモバイル変換

https://www.whocc.no/atc_ddd_index/?code=L04AA10

14 February 2018

3milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

sirolimus(English)

1 reference

Streptomyces hygroscopicus

Sirolimus(English)

19 January 2016

19 references

Incorporation of acetate, propionate, and methionine into rapamycin by Streptomyces hygroscopicus

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans

Cytochrome p450 complement (CYPome) of the avermectin-producer Streptomyces avermitilis and comparison to that of Streptomyces coelicolor A3(2).

Organization of the biosynthetic gene cluster for the macrolide concanamycin A in Streptomyces neyagawaensis ATCC 27449.

A combined approach of classical mutagenesis and rational metabolic engineering improves rapamycin biosynthesis and provides insights into methylmalonyl-CoA precursor supply pathway in Streptomyces hygroscopicus ATCC 29253

Waking up Streptomyces secondary metabolism by constitutive expression of activators or genetic disruption of repressors

Effects of dissolved oxygen level on rapamycin production by pellet-form of Streptomyces hygroscopicus

Studies on process optimization methods for rapamycin production using Streptomyces hygroscopicus ATCC 29253.

Production of rapamycin in Streptomyces hygroscopicus from glycerol-based media optimized by systemic methodology

Draft Genome Sequence of Streptomyces iranensis.

Discovery of actinoplanic acid pathway in reveals a genetically conserved synergism with rapamycin

Carbon source nutrition of rapamycin biosynthesis in Streptomyces hygroscopicus

Organisation of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase

An amplifiable and deletable locus of Streptomyces ambofaciens RP181110 contains a very large gene homologous to polyketide synthase genes

The Pipecolate‐Incorporating Enzyme for the Biosynthesis of the Immunosuppressant Rapamycin — Nucleotide Sequence Analysis, Disruption and Heterologous Expression of Rap P from Streptomyces Hygroscopicus

Effect of nitrogen source on biosynthesis of rapamycin by Streptomyces hygroscopicus

A second type-I PKS gene cluster isolated from Streptomyces hygroscopicus ATCC 29253, a rapamycin-producing strain

Isolation and Structure of Homotemsirolimuses A, B, and C

Streptomyces iranensis

16 references

Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans

Cytochrome p450 complement (CYPome) of the avermectin-producer Streptomyces avermitilis and comparison to that of Streptomyces coelicolor A3(2).

Organization of the biosynthetic gene cluster for the macrolide concanamycin A in Streptomyces neyagawaensis ATCC 27449.

Waking up Streptomyces secondary metabolism by constitutive expression of activators or genetic disruption of repressors

Effects of dissolved oxygen level on rapamycin production by pellet-form of Streptomyces hygroscopicus

Studies on process optimization methods for rapamycin production using Streptomyces hygroscopicus ATCC 29253.

Production of rapamycin in Streptomyces hygroscopicus from glycerol-based media optimized by systemic methodology

Draft Genome Sequence of Streptomyces iranensis.

Discovery of actinoplanic acid pathway in reveals a genetically conserved synergism with rapamycin

Carbon source nutrition of rapamycin biosynthesis in Streptomyces hygroscopicus

Organisation of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase

An amplifiable and deletable locus of Streptomyces ambofaciens RP181110 contains a very large gene homologous to polyketide synthase genes

Effect of nitrogen source on biosynthesis of rapamycin by Streptomyces hygroscopicus

A second type-I PKS gene cluster isolated from Streptomyces hygroscopicus ATCC 29253, a rapamycin-producing strain

Streptomyces rapamycinicus

16 references

Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans

Cytochrome p450 complement (CYPome) of the avermectin-producer Streptomyces avermitilis and comparison to that of Streptomyces coelicolor A3(2).

Organization of the biosynthetic gene cluster for the macrolide concanamycin A in Streptomyces neyagawaensis ATCC 27449.

Waking up Streptomyces secondary metabolism by constitutive expression of activators or genetic disruption of repressors

Effects of dissolved oxygen level on rapamycin production by pellet-form of Streptomyces hygroscopicus

Studies on process optimization methods for rapamycin production using Streptomyces hygroscopicus ATCC 29253.

Production of rapamycin in Streptomyces hygroscopicus from glycerol-based media optimized by systemic methodology

Draft Genome Sequence of Streptomyces iranensis.

Discovery of actinoplanic acid pathway in reveals a genetically conserved synergism with rapamycin

Carbon source nutrition of rapamycin biosynthesis in Streptomyces hygroscopicus

Organisation of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase

An amplifiable and deletable locus of Streptomyces ambofaciens RP181110 contains a very large gene homologous to polyketide synthase genes

Effect of nitrogen source on biosynthesis of rapamycin by Streptomyces hygroscopicus

A second type-I PKS gene cluster isolated from Streptomyces hygroscopicus ATCC 29253, a rapamycin-producing strain

Purpureocillium

1 reference

Leucinostatins from Ophiocordyceps spp. and Purpureocillium spp. Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer

Ophiocordyceps

1 reference

medical condition treated

pachyonychia congenita

0 references

lymphangioleiomyomatosis

1 reference

Drug Indications Extracted from FAERS

graft-versus-host disease

2 October 2018

renal cell carcinoma

0 references

transplant rejection

0 references

1 reference

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

FKBP prolyl isomerase 1A

subject has role

enzyme inhibitor

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

6031

English

intraperitoneal injection

17 August 2016

route of administration

0 references

oral administration

0 references

intravenous infusion and defusion

0 references

legal status (medicine)

boxed warning

1 reference

reference URL

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

Australian pregnancy category C

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.(English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

produced by

Streptomyces rapamycinicus

0 references

subject has role

protein kinase inhibitors

1 reference

5 March 2018

1 reference

MeSH descriptor ID

D020123

antineoplastic antibiotics

15 March 2018

1 reference

15 March 2018

1 reference

MeSH descriptor ID

D020123

15 March 2018

immunosuppressive drug

1 reference

15 March 2018

2 references

C1212

1 reference

Library of Congress authority ID

14 February 2018

0 references

0 references

0 references

0 references

Sirolimus

0 references

Identifiers

J9U ID

987007542160305171

subject named as

רפמיצין

Rapamycin

alternative name

Sirolimus

0 references

sh2001005861

0 references

InChI

InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1

1 reference

Rapamycin(English)

21 September 2016

2 references

Rapamycin(English)

21 September 2016

14 February 2018

3 references

Sirolimus(English)

17 November 2015

14 February 2018

https://commonchemistry.cas.org/detail?cas_rn=53123-88-9

8 April 2021

1 reference

Sirolimus(English)

21 September 2016

2 references

English

Rapamycin(English)

21 September 2016

InChIKey

ChEBI ID

9168

mapping relation type

3 references

SIROLIMUS(English)

21 September 2016

ChEBI release 2021-03-01

International Chemical Identifier

1 reference

SIROLIMUS(English)

21 September 2016

2 references

inferred from InChIKey

InChIKey

Hazardous Substances Data Bank

1 reference

1 reference

28 October 2019

SIROLIMUS(English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

InChIKey

DSSTOX compound identifier

0 references

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.107.147

27 December 2018

ECHA Substance Infocard ID

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone(English)

quotation

CAS no.: 53123-88-9(English)

100.107.147

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.107.147

27 December 2018